Superficial vein thrombosis (SVT) is a blood clot that forms in a vein just beneath the skin’s surface, usually accompanied by inflammation of the vein wall. It most commonly occurs in the legs and typically shows up as a red, firm cord you can see and feel under your skin, along with warmth, swelling, and tenderness in the area. Once considered a minor nuisance, SVT is now recognized as a condition with real links to more serious clotting problems, including deep vein thrombosis and pulmonary embolism.
How a Clot Forms in a Superficial Vein
The process starts small. Microscopic clots develop when something disrupts normal blood flow in a surface-level vein. That disruption could be sluggish circulation, direct injury to the vein wall, or a change in how easily your blood clots. When any of these conditions persist, the tiny clots grow into larger ones that block the vein and trigger inflammation in the surrounding tissue.
The vein wall injury is especially effective at starting this chain reaction. Damage to the inner lining of the vein causes platelets to stick to the injured area almost immediately, and clotting proteins pile on to build up the blockage. This is why IV catheters, injections, and trauma to a vein are such reliable triggers for SVT.
What It Looks and Feels Like
The hallmark of SVT is a hard, rope-like cord running just under the skin that hurts when you touch it. The skin over the affected vein is typically red, warm, and swollen. The pain can range from mild tenderness to a persistent ache that worsens with movement or pressure. Unlike a deep vein clot, which often causes diffuse leg swelling, SVT tends to produce visible, localized signs right along the path of the affected vein.
Who Is Most at Risk
Varicose veins are the single biggest risk factor for SVT in the legs, present in roughly 90% of lower-limb cases. The sluggish, turbulent blood flow inside dilated varicose veins creates ideal conditions for clots to form. Beyond varicose veins, the risk factors overlap heavily with those for deep vein thrombosis: older age, obesity, pregnancy, recent surgery, prolonged immobilization, cancer, autoimmune diseases, and use of oral contraceptives or hormone therapy.
Inherited clotting disorders also play a significant role. People with SVT are two to three times more likely to carry genetic thrombophilia factors (such as Factor V Leiden or deficiencies in natural anticoagulant proteins) compared to people without SVT. This suggests that the underlying biology driving superficial and deep vein clots is more similar than doctors once thought.
In the upper body, SVT has a different profile. Arm and hand SVT is usually caused by IV catheters used for chemotherapy, IV nutrition, or other hospital infusions, making it a common complication in hospitalized patients.
How It’s Diagnosed
Doctors can often diagnose SVT just by looking at and feeling the affected area. A firm, thickened vein with surrounding redness and pain is usually enough to make the call. But the physical exam alone can’t tell you how far the clot extends, how close it is to the deep venous system, or whether a deep vein clot is already present.
That’s where ultrasound comes in. Duplex ultrasound is the standard imaging tool, and it provides critical details: the exact location of the clot, its length, and how close it sits to the junctions where superficial veins connect to deep veins. The test works by checking whether the vein can be compressed (a clotted vein won’t flatten under pressure) and by looking for abnormal blood flow patterns. Its sensitivity and specificity both range from 80% to 100%, making it highly reliable.
The results of the ultrasound directly shape treatment decisions. A clot longer than 5 cm, or one sitting within 3 cm of the junction where the great saphenous vein meets the deep femoral vein, carries a higher risk of complications and typically calls for more aggressive treatment.
The Connection to Deep Vein Thrombosis
This is the part of SVT that changed how doctors think about the condition. The reported rate of concurrent deep vein thrombosis in people who show up with SVT ranges from about 6% to 40%, depending on the study and the population. In one large study of 844 patients with SVT, a full 25% already had a coexisting deep vein clot at the time of diagnosis.
Even among those who initially present without DVT or pulmonary embolism, about 10% develop a thromboembolic complication within three months. Clots in the great saphenous vein near its junction with the deep system are especially concerning. One study found a 24% rate of progression to DVT in patients with clots in that area who didn’t receive blood thinners. Asymptomatic pulmonary embolism, detected only on lung scans, may occur in up to a third of SVT patients.
The mechanism is straightforward: the clot can grow along the superficial vein until it reaches a junction point where the superficial and deep venous systems connect, then extend into the deep vein. From there, a piece can break off and travel to the lungs.
Treatment Options
For mild, limited SVT, self-care measures are often sufficient. Applying a warm washcloth to the area several times a day, elevating the affected leg, and taking an over-the-counter anti-inflammatory like ibuprofen or naproxen can ease the pain and inflammation. Compression stockings may also help. If you’re already taking a blood thinner like aspirin, let your doctor know before adding an anti-inflammatory.
For more extensive SVT, particularly clots longer than 5 cm in the lower legs, anticoagulant therapy is the standard approach. Current clinical guidelines recommend a low-dose injectable blood thinner called fondaparinux, given once daily for 45 days. This recommendation is based largely on a major trial of over 3,000 patients, which showed the treatment significantly reduced the risk of the clot extending or progressing to DVT and pulmonary embolism. Alternative blood thinners, including certain oral options, are considered reasonable substitutes when fondaparinux isn’t suitable.
Recovery and What to Watch For
Most people with SVT improve steadily. In one study tracking patients with serial ultrasounds, about 88% showed no worsening or had significant improvement by their scheduled follow-up. The inflammatory symptoms, like redness, warmth, and tenderness, typically begin to fade within the first couple of weeks, though it can take longer for the hardened cord under the skin to fully resolve. Some people notice a brownish discoloration along the vein that lingers for weeks to months after the acute episode.
The signs that warrant urgent attention relate to clot progression. New or worsening swelling of the entire limb (not just the area around the vein) suggests the clot may have extended into the deep venous system. Shortness of breath, chest pain, or a rapid heartbeat could indicate a pulmonary embolism. If the original area of redness and hardness begins spreading noticeably along the vein, particularly toward the groin or the back of the knee, that suggests the clot is growing toward a junction with the deep veins.